Denali Therapeutics Inc. (DNLI) Tops Q2 EPS by 8c
Tweet
Share
E-mailGet Alerts DNLI Hot Sheet
Join SI Premium – FREE
Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.59), $0.08 better than the analyst estimate of ($0.67).
For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
- JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
